Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ENZ | Enzo Biochem, Inc.

Index- P/E- EPS (ttm)-0.93 Insider Own9.70% Shs Outstand49.38M Perf Week5.38%
Market Cap72.29M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float36.05M Perf Month-14.91%
Income-45.60M PEG- EPS next Q- Inst Own42.20% Short Float / Ratio4.08% / 4.33 Perf Quarter-28.27%
Sales71.00M P/S1.02 EPS this Y-330.60% Inst Trans-2.74% Short Interest1.47M Perf Half Y-35.68%
Book/sh0.38 P/B3.61 EPS next Y- ROA-55.30% Target Price- Perf Year-39.38%
Cash/sh0.05 P/C27.81 EPS next 5Y- ROE-120.60% 52W Range1.00 - 2.74 Perf YTD-4.20%
Dividend- P/FCF- EPS past 5Y-47.40% ROI-25.50% 52W High-50.00% Beta0.96
Dividend %- Quick Ratio0.40 Sales past 5Y0.40% Gross Margin15.30% 52W Low37.00% ATR0.07
Employees465 Current Ratio0.80 Sales Q/Q-38.50% Oper. Margin-65.70% RSI (14)40.18 Volatility5.55% 4.53%
OptionableYes Debt/Eq0.40 EPS Q/Q-208.60% Profit Margin-64.20% Rel Volume0.16 Prev Close1.37
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume340.35K Price1.37
Recom- SMA20-6.45% SMA50-8.02% SMA200-21.84% Volume55,586 Change0.00%
Date Action Analyst Rating Change Price Target Change
Oct-18-11Reiterated Rodman & Renshaw Mkt Outperform $7 → $5
Sep-23-09Initiated Rodman & Renshaw Mkt Outperform $14
Sep-13-07Initiated Lazard Capital Buy $19
Sep-06-23 08:30AM
Jul-31-23 06:28AM
Jul-24-23 04:27PM
Jun-14-23 07:21PM
08:36AM Loading…
Jun-08-23 08:36AM
May-22-23 09:20AM
May-14-23 10:12AM
Apr-24-23 04:05PM
Apr-17-23 06:29AM
Mar-22-23 06:04AM
Mar-21-23 10:11AM
Mar-18-23 08:02AM
Mar-16-23 04:30PM
08:47AM Loading…
Dec-16-22 08:47AM
Dec-12-22 05:29PM
Dec-07-22 06:18PM
Nov-18-22 09:31AM
Nov-08-22 06:04PM
Oct-31-22 08:30AM
Oct-20-22 08:15AM
Oct-17-22 08:51AM
Oct-14-22 07:30AM
Oct-10-22 11:31AM
Oct-06-22 08:00AM
Sep-26-22 08:00AM
Aug-30-22 12:12PM
Aug-11-22 08:00AM
Aug-03-22 08:00AM
09:00AM Loading…
Jul-04-22 09:00AM
Jun-11-22 10:29AM
Jun-09-22 04:30PM
Jun-06-22 08:30AM
Jun-02-22 05:05PM
May-09-22 11:57AM
Apr-19-22 08:00AM
Apr-12-22 08:30AM
Apr-06-22 04:57PM
Apr-01-22 08:00AM
Mar-28-22 04:17PM
Mar-23-22 04:41PM
Mar-21-22 08:13AM
Mar-14-22 04:10PM
Mar-10-22 08:38AM
Mar-08-22 08:29AM
Jan-22-22 08:16AM
Jan-20-22 05:38PM
Jan-14-22 09:38AM
Jan-03-22 04:10PM
Dec-15-21 04:05PM
Dec-06-21 08:38PM
Dec-02-21 04:05PM
Nov-23-21 06:26AM
Nov-09-21 10:18AM
Oct-25-21 08:00AM
Oct-21-21 08:38AM
Oct-19-21 07:00AM
Oct-18-21 08:17AM
Oct-12-21 07:00AM
Sep-28-21 08:00AM
Sep-12-21 09:35AM
Sep-02-21 04:05PM
Jul-20-21 08:00AM
Jul-14-21 02:32AM
Jun-15-21 12:00PM
Jun-09-21 04:05PM
Jun-01-21 04:05PM
May-15-21 04:24AM
May-05-21 12:05PM
Apr-21-21 08:00AM
Mar-31-21 03:41AM
Mar-17-21 04:15PM
Mar-16-21 09:59AM
Mar-15-21 04:05PM
Mar-12-21 08:00AM
Mar-04-21 08:00AM
Mar-02-21 08:00AM
Mar-01-21 04:05PM
Feb-03-21 08:30AM
Jan-30-21 03:37AM
Jan-22-21 07:26PM
Jan-20-21 08:14AM
Jan-15-21 11:39AM
Jan-05-21 01:27PM
Jan-04-21 07:00AM
Dec-31-20 07:30PM
Dec-28-20 08:00AM
Dec-24-20 02:06PM
Dec-15-20 08:00AM
Dec-10-20 07:53PM
Dec-09-20 04:01PM
Dec-02-20 08:00AM
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wolf James G.10% owner until 2/13/2023Feb 13Buy1.295,0006,450115,000Feb 13 09:41 PM
Wolf James G.10% owner until 2/13/2023Feb 13Buy1.285,0006,4254,100,000Feb 13 09:41 PM
Wolf James G.10% owner until 2/13/2023Feb 10Buy1.295,0006,4504,095,000Feb 13 09:41 PM
Wolf James G.10% OwnerJan 27Buy1.4011,80016,5204,090,000Jan 30 12:01 PM
Erfanian HamidChief Executive OfficerNov 23Buy1.97100,000197,000374,600Nov 28 06:27 PM
Wolf James G.10% OwnerNov 01Buy2.148,50018,225418,500Jan 19 02:37 PM
Wolf James G.10% OwnerOct 31Buy2.1514,50031,175415,000Jan 19 02:37 PM